Drugs / BGM0504
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07566572 | Mar → Sep 2026 overdue | — | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07239973 | Oct 2025 → Mar 2026 overdue | — | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07166081 | Aug 2025 → Jan 2026 overdue | — | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06929156 | May → Dec 2025 | obesity disorder, type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06920056 | Mar → Jul 2025 | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06714955 | Oct 2024 → Jan 2025 | — | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06911203 | Apr 2025 → Jan 2026 overdue | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07836140 | Apr 2024 → Apr 2025 | obesity disorder | Second Affiliated Hospital of Soochow University | Completed | No outcome recorded |
| Phase 2 | NCT06973681 | Oct 2023 → Sep 2024 | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06974825 | Aug 2023 → Aug 2024 | type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07064486 | Jul 2025 → Jul 2026 overdue | type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06716203 | Dec 2024 → Dec 2025 overdue | type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06716216 | Nov 2024 → Mar 2026 overdue | type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06704581 | Oct 2024 → Nov 2025 overdue | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGM0504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06716216 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC) once a week.” NCT06704581 ↗ |